Harpreet Singh, MD, former director of the FDA's Division of Oncology 2 and chief medical officer of Precision for Medicine, discusses the FDA's draft guidance on the use of overall survival (OS) as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback